Listing & Compliance Notices

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 30, 2025, Palisade Bio, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq Cap”

Nine Energy Service, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“April 30, 2025, Nine Energy Service, Inc. (the “Company”) received written notification (the “Price Criteria Notice”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing share price of the Company’s common stock, par value $0.01 per share (the “Common Stock”), was less than $1.00 over a consecutive 30 trading-day period. The Company plans to notify the NYSE within the required timeframe that it intends to cure the stock price deficiency and regain compliance. Under the NYSE’s rule”

HYPERION DEFI, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 29, 2025, Eyenovia, Inc. (the “Company”) received a notice (the “Notice”) from the staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1) (the “Minimum Equity Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market, which continues to trade under the symbol “EYEN”. In accordance with”

CISO Global, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 30, 2025, we received a letter from the listing qualifications staff (the “Staff”) of Nasdaq providing notification that the bid price for our common stock had closed below $1.00 per share for the previous 31 consecutive business days and our common stock no longer meets the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have an initial period of 180 calendar days, or until October 27, 2025, to regain compliance. To regain compliance, the closing bid price of our common stock must be $1.00”

Nautilus Biotechnology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

“rice of shares of the Company’s common stock for the 30 consecutive business day period between March 19, 2025, through April 30, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until October 28, 2025 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter has no immediate impact on the listing o”

Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A)(iii), 5810(d)).

“April 28, 2025, Nasdaq notified the Company (the “ Notice ”) it had public interest concerns regarding the Company’s public offering of securities that closed on February 19, 2025, which serves as an additional basis for delisting the Company’s securities pursuant to Nasdaq Listing Rule 5810(d). The Company intends to address these concerns before a Nasdaq Hearings Panel (the “ Panel ”). As a result of the Company’s hearing request pending appeal notice, all delisting actions have been stayed, pending a hearing before the Panel. The Notice has no immediate impact on the Company’s common stock”

Distoken Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)).

“April 29, 2025, Distoken Acquisition Corporation (the “ Company ”) received a deficiency letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“ MVPHS ”) was below the $15 million minimum requirement under the continued listing standards of The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2) (the “ MVPHS Requirement ”). The notification received has no immediate effect on the Company’s Nasdaq listing.”

Hyperfine, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

“April 30, 2025, Hyperfine, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). This Notice”

SunPower Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 28, 2025, Complete Solaria, Inc. (the “Company”) received an expected letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”), the Company was not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). The Nasdaq letter has no immediate effect on the listing or trading of the Company’s common stock or warrants. The Company’s Form 12b-25 Notification of”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 28, 2025, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until April 30, 2024 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by October 27, 2025, the Company may be eligible for an additional 180-day period to”

MOBIX LABS, INC received a nasdaq noncompliance notice notice regarding market value (rules 5550(a)(2), 5550(b)(2)).

“Requirement”). Nasdaq Listing Rule 5550(b)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum market value of listed securities (“MVLS”) of at least $35 million (the “MVLS Requirement”). The Notices stated that, as of their date, the bid price of the Company’s Class A Common Stock, par value $0.00001 per share (“Common Stock”) was below”

MOBIX LABS, INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2)).

“April 28, 2025, Mobix Labs, Inc. (the “Company”) received two delinquency notification letters (the “Notices”) from the Listing Qualifications Staff (the “Staff”) of Nasdaq stating that the Company was not in compliance with the minimum bid price requirement and the market value of listed securities requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum bid price of at least $1.00 per share (the “Minimum Bid Price Requirement”). Nasdaq Listing Rule 5550(b)(2) requires companies”

PHOENIX MOTOR INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 30, 2025, Phoenix Motor Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with Listing Rule 5250(c)(1) due to its failure to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”). This matter serves as an additional basis for delisting the Company’s securities from Nasdaq. As previously disclosed, on April 8, 2025, the Company received a determination letter from the Staff (the “Staff Dete”

AIxCrypto Holdings, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)).

“April 24, 2025, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the Company is delinquent in filing the 2024 Form 10-K, the Company no longer complies with Nasdaq Listing Rule 5250(c) (the “Listing Rule”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. Therefore, in line with the Panel Monitor’s decision, the Company’s securities will be delisted from Nasdaq. If the Company does not request an appeal of this decision by May 1, 2025, trading of the C”

American Resources Corp received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, American Resources Corporation (or the “Company”) received a letter from the Nasdaq Stock Market indicating that the company’s Form 10-K for the fiscal year ended December 31, 2024 has not been timely filed according to Nasdaq’s Listing Rules. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s stock on the Nasdaq Capital Market. Under the Listing Rules, the Company has 60 days to file a plan to file its 10-K and then 180 days post acceptance of the plan to file at which point the Company will regain compliance with the listing r”

Adaptimmune Therapeutics PLC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“May 1, 2025, Adaptimmune Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) approving the transfer of the listing of the Company’s American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Approval”). As previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission, on November 1, 2024, the Company received a notice from Nasdaq that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), because the minimum bid price of the Company’s ADSs has been be”

Cenntro Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 25, 2025 (the “Notification Date”), Cenntro Inc. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock was below $1.00 per share for thirty consecutive business days. The Notice does not impact the listing of the Company’s common stock on the Nasdaq Capital Market. In accord”

MSP Recovery, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 24, 2025, MSP Recovery, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($128,409,000), as reported in the Company’s Form 10-K for the year ended December 31, 2024, was below the required minimum of $2.5 million, and because, as of April 24, 2025, the Company did not meet”

Aimfinity Investment Corp. I received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“April 28, 2025, the Company received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company did not comply with Nasdaq Interpretive Material IM-5101-2 (“IM-5101-2”), and that its securities are now subject to delisting. The Company’s registration statement, filed in connection with the Company’s initial public offering (“IPO”), became effective on April 25, 2022. Pursuant to IM-5101-2, the Company, a special purpose acquisition company, must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statem”

ABVC BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 24, 2025, we received a letter from the listing qualifications staff (the “ Staff ”) of Nasdaq informing us that, as reported in our Annual Report on Form 10-K for the year ended December 31, 2024, because our stockholders’ equity was $723,959, as of April 23, 2025, we did not meet the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with the Listing Rule. We have 45 calendar days to submit a plan to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar days from the”

BioNexus Gene Lab Corp received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“April 30, 2025, BioNexus Gene Lab Corp. (the “Company”) received a formal notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The Company was previously notified of non-compliance with the Bid Price Rule and appeared before the Panel pursuant to Docket No. NQ 7050C-24. As of April 23, 2025, the Company’s common stock had maintained a closing bid price of $1.00 or greater for the requisite number of consecutive business day”

Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, Onconetix, Inc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “ 10-K ”), and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. As previously reported in the Current Report on Form 8-K filed with the Secu”

Leslie's, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 24, 2025, Leslie’s, Inc. (the “Company”) received notification (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s common stock is subject to potential delisting from The Nasdaq Global Select Market because, for a period of 30 consecutive business days, the bid price of the Company’s common stock has closed below the minimum $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Notice has no immediate impact on the Company’s listing on The Nasdaq Glob”

GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2), 5810(c)(3)(D)).

“April 25, 2025, Graphjet Technology (the “Company” or “Graphjet”), received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the Company’s market value of publicly held shares (“MVPHS”) closed below the $15,000,000 MVPHS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2) (the “MVPHS Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has 180 calendar days, or until October”

Oak Woods Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, Oak Woods Acquisition Corporation (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the period ended December 31, 2024 (the “Annual Report”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). The Notice states that the Company ha”

Damon Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5810(d), 4120(a)(5)).

“April 25, 2025, Damon Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the Company’s issuance of securities pursuant to the underwriting agreement dated March 20, 2025, particularly the Serie”

ARTELO BIOSCIENCES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 23, 2025, Artelo Biosciences, Inc. (the “ Company ”) received written notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, subject to Nasdaq’s discretion, the closing bid price of the Compa”

Sonder Holdings Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the Company is delinquent in filing the 2024 Form 10-K, the Company no longer complies with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock or publicly traded warrants on the Nasdaq Global Select Market. In accordance with Nasdaq’s listing rules”

Global Interactive Technologies, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, Global Interactive Technologies, Inc. (the “Company”) received written notice (the “Nasdaq Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it did not timely file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”), as required for continued listing on The Nasdaq Stock Market pursuant to Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has 60 calendar days from the date of the Nasdaq Notification Letter to submit to Nasdaq a plan to regain compli”

Health In Tech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 28, 2025, Health In Tech, Inc. (the “Company”) received a letter (the “Nasdaq Staff Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s Class A common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 27, 2025, to regain compliance. The letter stat”

AgEagle Aerial Systems Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of December 31, 2024, the Company had stockholders’ deficit of $5.7 million and has had losses in the most recent five fiscal years ended December 31, 2024. The Company is now subject to the procedures and requirements of Section 1009 of the Company”

AMARIN CORP PLCUK received a nasdaq compliance regained notice regarding minimum bid price (rules 5450(a)(1)).

“April 29, 2025, Amarin Corporation plc (the “Company”) received written confirmation from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). Consequently, the Company is now in compliance with all applicable listing standards and will continue to be listed on the Nasdaq Capital Market. As previously disclosed, the Company was previously notified by the Staff that the Company was not in”

YUNHONG GREEN CTI LTD. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 21, 2024, Yunhong Green CTI Ltd. (“CTI” or the “Company”), received written notice (the “Notice”) from The Nasdaq Capital Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notice provided an initial 180 calendar day period, or until April 21, 2025, in which to regain compliance, pu”

NextPlat Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A), 5550(a)(2)).

“April 28, 2025, NextPlat Corp (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the minimum closing bid price per share for its common stock was below $1.00 for 30 consecutive business days preceding the date of the Notice, and that the Company did not meet the $1.00 per share minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market. Pursuant to Nasd”

NOCERA, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, Nocera, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”). The letter has no immediate effect on the listing of the Company’s common stock, which will continue to trade on Nasdaq under the symbol “NCRA”. Under Nasdaq rules, the Company has sixty (60) calendar days from the date of the notice to submit a plan to regain compliance. If Nasdaq ac”

KUSTOM ENTERTAINMENT, INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“April 23, 2025, Digital Ally, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the period ended December 31, 2024 (the “Annual Report”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). The Notice states that the Company has until April 30, 2025 to present”

Nixxy, Inc. received a nasdaq compliance regained notice regarding other (rules 5608(b)(1), 5608(b)(2)).

“April 23, 2025, Nixxy, Inc. (the “Company”) received a letter from the Nasdaq Stock Exchange informing them that it did not adopt a written policy for the recovery of erroneously awarded compensation as required by Listing Rule 5608(b)(1), and did not disclose the policy in either the Form 10-K for the fiscal years ended December 31, 2023 or December 31, 2024, and as a result, did not comply with Listing Rule 5608(b)(2). Subsequently, on January 1, 2025, the Company’s a compensation recovery policy went effective and included such policy in an amended Form 10-K for the fiscal year ended Decemb”

Decoy Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5810(d)(2)).

“March 26, 2025, the Company received a letter from Nasdaq notifying the Company that, based on the financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2024, the Company no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market (the “Equity Standard”). The letter indicated that the Company had until May 12, 2025 to either regain compliance with the Equity Standard or submit a plan to Nasdaq to regain compliance with the”

Decoy Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“April 23, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq”

SPRUCE BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5815(a)(1)(B)(ii)(d), 5810(c)(3)(A)(ii), 5800).

“pects that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company has appealed Nasdaq’s determination to its Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will not stay the trading suspension of the Company’s common stock as the Company was afforded the second 180 days compliance period described in Nasdaq Listing Rule 5810(c)(3)(A)(ii) and”

ALX ONCOLOGY HOLDINGS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“April 23, 2025, ALX Oncology Holdings Inc. (the “Company”) received a written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has not been in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market set forth in Nasdaq Listing Rule 5450(a)(1) for a period of 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing of the Company’s stock on the Nasdaq Global Select Market, subject to the Company’s compliance with the other lis”

Vor Biopharma Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“April 22, 2025, Vor Biopharma Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance”

Wheels Up Experience Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“April 22, 2025, Wheels Up Experience Inc. (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”), which requires listed companies to maintain an average closing price per share of at least $1.00 over a 30 consecutive trading-day period. The Company has six months after receipt of the Notice (the “Cure Period”) to regain compliance with Section 802.01C, which requires that during the Cure Period the Company’s Class A common stock, $0.0001 par valu”

Invivyd, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“April 21, 2025, Invivyd, Inc. (the “Company”) received a deficiency letter (the “ Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for a period of 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the listi”

AEON Biopharma, Inc. received a nyse_american extension granted notice regarding other (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“April 22, 2025, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Plan was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 3, 2026 (the “Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide d”

CITIUS ONCOLOGY, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 23, 2025, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until October 20, 2025, to regain compliance with the Bid Price Rule. If at any time before October 20, 2025, the bid”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). This Notice is only a notification of a deficiency and has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Global Market under the symbol “IXHL.” Pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180 calendar days, or until October 20, 2025 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company’s Common Stock must m”

iCoreConnect Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“April 24, 2025, the Company received notification from the Panel that it has granted an extension until May 15, 2025 to file its Form 10-K for the period ended December 31, 2024, and until June 30, 2025, to demonstrate compliance with all continued listing requirements for the Nasdaq Capital Market. The notification received by the Company also served as a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D) due to the Company’s failure to promptly disclose the information in its Form 8-K dated March 26, 2025 pursuant to Listing Rule 5250(b)(1) and due to its failure to includ”

iCoreConnect Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 24, 2025, the Company received notification from the Panel that it has granted an extension until May 15, 2025 to file its Form 10-K for the period ended December 31, 2024, and until June 30, 2025, to demonstrate compliance with all continued listing requirements for the Nasdaq Capital Market. The notification received by the Company also served as a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D) due to the Company’s failure to promptly disclose the information in its Form 8-K dated March 26, 2025 pursuant to Listing Rule 5250(b)(1) and due to its failure to includ”

Aureus Greenway Holdings Inc received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“April 23, 2025, Aureus Greenway Holdings Inc.(the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company did not comply with the minimum $2.5 million stockholders’ equity, $35 million market value of listed securities (“MVLS”), or $500,000 of net income from continuing operations requirements for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), respectively. The Notice is only a notification of deficie”